Showing 3751-3760 of 5646 results for "".
- Ocugen Completes Dosing in Phase 1/2 Trial of OCU410 for Geographic Atrophyhttps://modernod.com/news/ocugen-advances-armada-trial-of-ocu410-to-treat-patients-with-geographic-atrophy/2482238/Ocugen announced dosing is complete in the second cohort of its phase 1/2 ArMaDa trial of OCU410, an adeno-associated viral vector 5 human RORA (AAV5-hRORA) gene therapy being developed for geographic atrophy (GA). Up to 13
- Ocular Therapeutix Releases Topline Results for Phase 1 Trial of Axpaxli for Diabetic Retinopathyhttps://modernod.com/news/ocular-therapeutix-axpaxli-in-diabetic-retinopathy-evaluated-in-phase-1-helios-clinical-trial/2482237/Ocular Therapeutix announced positive topline results from the phase 1 HELIOS study, which is evaluating the safety, tolerability, and efficacy of drug candidate Axpaxli versus a sham control in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) without di
- EyeSouth Partners Affiliates With Community Eye Care Specialists in New Yorkhttps://modernod.com/news/eyesouth-partners-affiliates-with-community-eye-care-specialists-in-new-york/2482233/EyeSouth Partners announced it has partnered with Community Eye Care Specialists, representing its first affiliation in New York, third affiliation in Pennsylvania. and 40th affiliation overall. Financial terms of the deal were not disclosed. EyeSouth is an eye care-focused ma
- In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streakshttps://modernod.com/news/in-japanese-study-vabysmo-achieves-primary-endpoint-in-phase-3-study-for-angioid-streaks/2482231/Japan-based Chugai Pharmaceutical announced that the Japanese phase 3 study (NIHONBASHI study), evaluating Roche and Genentech's Vabysmo (faricimab) for angioid streaks associated with neovascularization, met its primary endpoint, demonstrating statistically signific
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- Oasis Medical Introduces SOFT PLUG Extended Duration 180-T Tapered Plughttps://modernod.com/news/orasis-introduces-soft-plug-extended-duration-180-t-tapered-plug/2482222/Oasis Medical has launched the SOFT PLUG Extended Duration 180-T Tapered Plug. SOFT PLUG Extended Duration 180-T Tapered Plugs are designed with a .25mm tapered end for ease of insertion into the punctal opening, according to Oasis. The plug then gradu
- FDA Approves Ocugen's IND Amendment to Initiate Phase 3 Trial for RP Gene Therapyhttps://modernod.com/news/fda-approves-ocugens-ind-amendment-to-initiate-phase-3-trial-for-rp-gene-therapy/2482220/Ocugen announced that the FDA has cleared the company’s investigational new drug (IND) amendment to initiate a phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “The initiation of the OCU400 phase
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- TheiaNova Selected as Finalist at Eyecelerator for Keratoconus Therapy; Launches Capital Raise for Clinical Trialshttps://modernod.com/news/theianova-selected-as-finalist-at-eyecelerator-for-keratoconus-therapy-launches-capital-raise-for-clinical-trials/2482215/New Zealand-based TheiaNova has delivered the company’s pitch as a finalist in the renowned Eyecelerator event in Boston. At the Eyecelerator event, where TheiaNova participated as a finalist, CEO Carissa Fonseca announced the company’s efforts to raise $10 million 
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont